HL 2351

Drug Profile

HL 2351

Alternative Names: GX P4; GX-P4 - Genexine; HL2351; Recombinant human interleukin-1 receptor antagonist hybrid Fc; rhIL-1Ra-hyFc

Latest Information Update: 31 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genexine
  • Developer Handok Inc
  • Class Anti-inflammatories; Antirheumatics; Biobetters; Biological proteins; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins
  • Mechanism of Action Interleukin 1 receptor antagonists; Interleukin 6 inhibitors; Interleukin-8 expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cryopyrin-associated periodic syndromes; Rheumatoid arthritis

Most Recent Events

  • 31 Aug 2017 Discontinued - Phase-I for Rheumatoid arthritis in South Korea (SC)
  • 31 Aug 2017 Discontinued - Phase-II for Cryopyrin associated Periodic Syndromes (In children, In the elderly, In adults) in South Korea (unspecified route)
  • 03 Jan 2017 Handok Pharmaceuticals terminates a phase II trial in Cryopyrin associated Periodic Syndromes (In children, In adults, In the elderly) in South Korea due to difficulty in recruiting patients (NCT02853084)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top